State of Alaska Department of Revenue Has $21.88 Million Stock Holdings in Intuitive Surgical, Inc. $ISRG

Key Points

• The State of Alaska Department of Revenue has reduced its stake in Intuitive Surgical, Inc. by 3.7%, now holding 40,259 shares valued at approximately $21.88 million.
• Intuitive Surgical reported earnings of $2.19 per share for the last quarter, exceeding analysts' expectations and showing a 21.4% year-over-year revenue increase.
• Recent analyst ratings show a consensus of "Moderate Buy" for Intuitive Surgical, with a target price averaging $595.95 per share.

State of Alaska Department of Revenue decreased its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 3.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 40,259 shares of the medical equipment provider's stock after selling 1,530 shares during the period. State of Alaska Department of Revenue's holdings in Intuitive Surgical were worth $21,877,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. Chilton Capital Management LLC boosted its position in shares of Intuitive Surgical by 614.3% during the 1st quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock worth $25,000 after acquiring an additional 43 shares in the last quarter. Global Financial Private Client LLC boosted its position in shares of Intuitive Surgical by 253.3% during the 1st quarter. Global Financial Private Client LLC now owns 53 shares of the medical equipment provider's stock worth $26,000 after acquiring an additional 38 shares in the last quarter. Elite Financial Inc. acquired a new stake in shares of Intuitive Surgical during the 1st quarter worth approximately $26,000. LFA Lugano Financial Advisors SA acquired a new stake in shares of Intuitive Surgical during the 1st quarter worth approximately $30,000. Finally, TD Capital Management LLC lifted its stake in Intuitive Surgical by 300.0% in the 1st quarter. TD Capital Management LLC now owns 60 shares of the medical equipment provider's stock valued at $30,000 after purchasing an additional 45 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company's stock.

Intuitive Surgical Stock Up 0.7%

Shares of NASDAQ ISRG opened at $441.12 on Friday. Intuitive Surgical, Inc. has a twelve month low of $425.00 and a twelve month high of $616.00. The firm has a fifty day simple moving average of $469.43 and a 200 day simple moving average of $501.46. The company has a market capitalization of $158.13 billion, a PE ratio of 61.52, a P/E/G ratio of 4.59 and a beta of 1.61.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share for the quarter, topping analysts' consensus estimates of $1.93 by $0.26. Intuitive Surgical had a net margin of 28.51% and a return on equity of 14.56%. The business had revenue of $2.44 billion during the quarter, compared to the consensus estimate of $2.35 billion. During the same quarter last year, the firm earned $1.78 earnings per share. Intuitive Surgical's quarterly revenue was up 21.4% on a year-over-year basis. As a group, equities analysts expect that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on ISRG. Erste Group Bank reissued a "hold" rating on shares of Intuitive Surgical in a research note on Wednesday, July 23rd. Royal Bank Of Canada reissued an "outperform" rating and issued a $615.00 price objective on shares of Intuitive Surgical in a research note on Tuesday, August 19th. Wall Street Zen downgraded shares of Intuitive Surgical from a "buy" rating to a "hold" rating in a research note on Friday. Zacks Research downgraded shares of Intuitive Surgical from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 20th. Finally, UBS Group increased their price objective on shares of Intuitive Surgical from $547.00 to $585.00 and gave the company a "neutral" rating in a research note on Wednesday, July 23rd. Thirteen equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Intuitive Surgical currently has a consensus rating of "Moderate Buy" and an average target price of $595.95.

Insider Buying and Selling

In other Intuitive Surgical news, Director Amy L. Ladd sold 336 shares of the firm's stock in a transaction on Wednesday, September 3rd. The shares were sold at an average price of $470.11, for a total value of $157,956.96. Following the completion of the sale, the director directly owned 1,074 shares in the company, valued at approximately $504,898.14. This trade represents a 23.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Gary S. Guthart sold 29,360 shares of the firm's stock in a transaction on Friday, August 29th. The stock was sold at an average price of $472.49, for a total transaction of $13,872,306.40. Following the completion of the sale, the insider owned 19,827 shares of the company's stock, valued at $9,368,059.23. The trade was a 59.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 45,224 shares of company stock valued at $21,716,492 over the last quarter. Insiders own 0.70% of the company's stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.